Your search for etanercept returned 113 results

Your search for etanercept returned 113 results

Sort Results:

Relevant Recent
Drug Monograph


Etanercept 25mg; per vial (pwd for SC inj after reconstitution; preservative-free; diluent contains benzyl alcohol); 25mg/0.5mL, 50mg/mL prefilled syringe (soln for SC inj; preservative free); 50mg/mL prefilled syringe SureClick autoinjector (soln for SC inj; preservative-free); 50mg/mL Enbrel Mini prefilled cartridge (soln for use with AutoTouch autoinjector only; preservative-free).
ACR/ARHP Annual Meeting 2015

Etanercept vs. Biosimilar: Which is More Effective?

The efficacy and safety profiles of SB4, an etanercept biosimilar, were comparable to those of etanercept in patients with moderate to severe rheumatoid arthritis (RA) to Week 52, according to study findings presented at the 2015 ACR/ARHP Annual Meeting.

Immunogenicity Strongly Impacts Response to Adalimumab in RA

For patients with rheumatoid arthritis (RA), long-term clinical outcomes are good with etanercept and adalimumab; but for adalimumab, treatment response is strongly dependent on the presence or absence of anti-adalimumab antibodies.
Drugs in the Pipeline

Ixekizumab Demonstrates Efficacy in Two Phase 3 Psoriasis Studies

Lilly announced positive results from two Phase 3 studies, UNCOVER-2 and UNCOVER-3, of ixekizumab for the treatment of moderate-to-severe plaque psoriasis compared to etanercept or placebo. Study findings were recently presented at the American Academy of Dermatology (AAD) Annual Meeting in Washington, D.C.

FDA Approves First Biosimilar to Enbrel

The Food and Drug Administration (FDA) has approved Erelzi (etanercept-szzs; Sandoz) injection, a biosimilar to Enbrel (etanercept; Amgen).